The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria

Citrobacter infections in a tertiary care hospital in Northern India

“…The antibiotics tested were (concentrations in mg) as follows: ceftazidime (30), cefotaxime (30), piperacillin (100), amikacin (30), netilmicin (30), ciprofloxacin (5), nitrofurantoin (300), piperacillin/ tazobactam (100/10), cefoperazone/sulbactam (75/10), ticarcillin/clavulanic acid (75/10), meropenem (10) and imipenem (10). Only the first isolate per patient was included in the analysis.…”

In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data

“…Previous in vitro and in vivo studies of a ␤-lactam antibiotic and sulbactam combination on bacteria producing ESBLs showed variable responses [6,7,11,[26][27][28][29][30][31][32][33][34]. In this study, piperacillin/sulbactam at a ratio of 2:1 significantly decreased the rate of ESBL-producing non-susceptible E. coli from 100% to 50% and decreased the MIC 50 from >128 mg/L to 16 mg/L compared with piperacillin alone.…”

“…Sulbactam is a penicillanic sulfone obtained by oxidation of the thiazolidine sulphur of penicillanic acid and is currently combined with ampicillin or cefoperazone in clinical use [4]. More recently, because of its specific in vitro activity against Acinetobacter species, sulbactam has been approved in some countries (Germany, Australia, Switzerland, China and Taiwan) as a single substance to be combined with piperacillin or other ␤-lactam antibiotics [5][6][7]. The combination of piperacillin and tazobactam has been demonstrated to be highly active against pathogens associated with nosocomial infections and is also active against many piperacillin-resistant isolates of staphylococci, Enterobacteriaceae and Bacteroides spp.…”

Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria

“…This combination, later used in man for intra-abdominal infections, fever in neutropenic cancer patients, lower respiratory infections and complicated urinary tract infections, has proved its efficacy (Bodey et al 1996;Drew et al 1998). The activity of these thirdgeneration Ceps antibiotics against various strains producing ESBLs could be improved in vitro by combining Sul with Cef (Zhang and Li 2001). Cef is particularly effective when used against bacteria that are resistant to other aminoglycosides, since its chemical structure makes it less susceptible to several inactivating enzymes.…”